Cannabis sativa use in adolescence and risk of psychosis: a systematic review / Uso de cannabis sativa na adolescência e risco de psicose: uma revisão sistemática


  • Marina Bertoldo Baeza Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Ricardo Silva dos Santos Durães
  • Antonio de Pádua Serafim



Cannabis, adolescence, psychosis, systematic review.


Background: Studies have pointed out the increased risk of developing psychosis in adulthood related to cannabis use during adolescence. Aim: To conduct a systematic review of the literature on the use of cannabis in adolescence and risk of psychosis.  Method: We conducted a systematic review in accordance with PRISMA guidelines. We searched by PubMed, PsycINFO, and SciELO database between 2010 and 2019. Results: After an accurate analysis, of the 8.673 records screened articles, we selected and included 32 original studies in this systematic review. The sample in the original papers totaled 81.049 participants, indicating an association between early use of cannabis and the onset of psychosis in 97.3% of the studies, with a robust variety of instruments used. It has been shown that early cannabis use, associated to genetic vulnerability, gender, duration of use, environmental and social factors, or the use of other drugs may lead to late development of schizophrenia whether compared with non-users. Conclusion: There is evidence that marijuana use is associated with the occurrence of psychosis in adolescence and later in life. However, other variables, such as social and biological aspects, should be considered. This shows the importance of educational programs of public policies on risks of cannabis and clear information to the population about several combination factors that might lead to trigger psychotic disorders, such as schizophrenia.




Gontiès B, Araújo L. Maconha: uma perspectiva histórica, farmacológica e antropológica. Rev Humanidades. 2003 Fev;4(7):47–63. Retrieved from http://

Costa JLGP, Maia LO, Orlandi-Mattos P, Villares JC, Esteves MAF. Neurobiologia da Cannabis: do sistema endocanabinoide aos transtornos por uso de Cannabis. J Bras Psiquiatr. 2011 Mai;60(2):111–122. doi:10.1590/S0047-20852011000200006

Jungerman F, Laranjeira R, Bressan RA. [Cannabis: how far is it harmful?] Br J Psychiatry. 2005 Mar ;27(1):5–6. doi:10.1590/S1516-44462005000100003

Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi:10.1016/j.biopsych.2015.07.028

Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014 Jun 5;370(23):2219-27. doi:10.1056/NEJMra1402309

Morin JG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, Conrod PJ. A Population-Based Analysis of the Relationship Between Substance Use and Adolescent Cognitive Development. Am J Psychiatry. 2019 Feb 1;176(2):98-106. doi:10.1176/appi.ajp.2018.18020202

Solowij N, Pesa N. (2010). [Cognitive abnormalities and cannabis use]. Br J Psychiatry. 2010 May;32:31–40. doi:10.1590/S1516-44462010000500006

Rabner J, Gottlieb S, Lazdowsky L, LeBel A. Psychosis following traumatic brain injury and cannabis use in late adolescence. Am J Addict. 2016 Mar;25(2):91-3. doi:10.1111/ajad.12338

Hodgins S, Larm P, Westerman J. Individuals developing schizophrenia are hidden among adolescent substance misusers. Psychol Med. 2016 Oct;46(14):3041-3050. doi:10.1017/S0033291716001781

Gomes VRR, Caniato A. [Adolescents on contemporaneity: subjective unfolding about divestment on virtual]. Contextos Clínicos. 2016 Jan;9(1):133–146. doi:10.4013/ctc.2016.91.12

Wagner M, Oliveira M. Habilidades sociais e abuso de drogas em adolescentes. Psicol Clin. 2007 Dec;19(2):101–116. doi:10.1590/S0103-56652007000200008

DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry. 2008 Mar;21(2):140-50. doi:10.1097/YCO.0b013e3282f51266

Battistella G, Fornari E, Annoni JM, Chtioui H, Dao K, Fabritius M, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014 Aug;39(9):2041-8. doi:10.1038/npp.2014.67

Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186-93. doi:10.2174/13816128113199990426

Crippa JA, Lacerda ALT, Amaro E, Filho GB, Zuardi AW, Bressan AR. [Brain effects of cannabis – neuroimaging findings]. Br J Psychiatry. 2005 Dec;27(1):70–78. doi:10.1590/S1516-44462005000100016

Large M, Di Forti M, Murray R. Cannabis: debated schizophrenia link. Nature. 2015 Nov 19;527(7578):305. doi:10.1038/527305e

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016 Sep;42(5):1262-9. doi:10.1093/schbul/sbw003

Lodhi RJ, Wang Y, Rossolatos D, MacIntyre G, Bowker A, Crocker C, et al. Investigation of the COMT Val158Met variant association with age of onset of psychosis, adjusting for cannabis use. Brain Behav. 2018 Sep;8(9):e01120. doi:10.1002/brb3.1120

Pamplona FA. [Cannabis-based medicine: what is it good for?] Revista da Biologia. 2014 Nov;13(1):28–35. doi:10.7594/revbio.13.01.05

Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: what the evidence says. Curr Psychiatr. 2011 Sep;10(9):49–58. Retrieved from 2017/1009CP_Pierre.pdf.

Pierre JM. Cannabidiol (CBD) for schizophrenia: Promise or pipe dream? Curr Psychiatr. 2019 May;18(5):12–16, 19–20. Retrieved from

Murnion B. Medicinal cannabis. Aust Prescr. 2015 Dec;38(6):212-5. doi:10.18773/austprescr.2015.072

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Research Methods & Reporting. 2009 Jul;339:1–27. doi:10.1136/bmj.b2700

Shahzade C, Chun J, DeLisi LE, Manschreck TC. Patterns in adolescent cannabis use predict the onset and symptom structure of schizophrenia-spectrum disorder. Schizophr Res. 2018 Jul;197:539-543. doi:10.1016/j.schres.2018.01.008

Mustonen A, Niemelä S, Nordström T, Murray GK, Mäki P, Jääskeläinen E, Miettunen J. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. Br J Psychiatry. 2018 Apr;212(4):227-233. doi:10.1192/bjp.2017.52

Mané A, Bergé D, Penzol MJ, Parellada M, Bioque M, Lobo A, et al. Cannabis use, COMT, BDNF and age at first-episode psychosis. Psychiatry Res. 2017 Apr;250:38-43. doi:10.1016/j.psychres.2017.01.045

McHugh MJ, McGorry PD, Yung AR, Lin A, Wood SJ, Hartmann JA, Nelson B. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med. 2017 Mar;47(4):616-626. doi: 10.1017/S0033291716002671

Carney R, Yung AR, Amminger GP, Bradshaw T, Glozier N, Hermens DF, Hickie IB, Killackey E, McGorry P, Pantelis C, Wood SJ, Purcell R. Substance use in youth at risk for psychosis. Schizophr Res. 2017 Mar;181:23-29. doi:10.1016/j.schres.2016.08.026

Bourque J, Afzali MH, O'Leary-Barrett M, Conrod P. Cannabis use and psychotic-like experiences trajectories during early adolescence: the coevolution and potential mediators. J Child Psychol Psychiatry. 2017 Dec;58(12):1360-1369. doi:10.1111/jcpp.12765

González-Pinto A, González-Ortega I, Alberich S, Ruiz de Azúa S, Bernardo M, Bioque M, Cabrera B, Corripio I, Arango C, Lobo A, Sánchez-Torres AM, Cuesta MJ; PEPs Group. Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. PLoS One. 2016 Aug 11;11(8):e0160949. doi:10.1371/journal.pone.0160949

Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF, Compton MT. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res. 2016 Mar;171(1-3):62-7. doi:10.1016/j.schres.2016.01.015

Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R, Bearden CE, Mathalon D, Addington J. Substance use in individuals at clinical high risk of psychosis. Psychol Med. 2015 Aug;45(11):2275-84. doi:10.1017/S0033291715000227

Smith MJ, Cobia DJ, Reilly JL, Gilman JM, Roberts AG, Alpert KI, et al. Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus. 2015 Sep;25(9):1042-51. doi:10.1002/hipo.22427

Buchy L, Cannon TD, Anticevic A, Lyngberg K, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. BMC Psychiatry. 2015 Nov 9;15:276. doi:10.1186/s12888-015-0656-x

Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, et al. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull. 2015 Sep;41(5):1171–1182. doi:10.1093/schbul/sbv032

Mané A, Fernández-Expósito M, Bergé D, Gómez-Pérez L, Sabaté A, Toll A, et al. Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Res. 2015 Sep 30;229(1-2):70-4. doi:10.1016/j.psychres.2015.07.070

Håkansson A, Johansson B. Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. J Med Case Reports. 2015 Sep;9(200):1–5. doi:10.1186/s13256-015-0678-5

Koenders L, Machielsen MWJ, Van Der Meer FJ, Van Gasselt ACM, Meijer CJ, Van Den Brink W, et al. Brain volume in male patients with recent on set schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci. 2015 Jan;40(3):197–206. doi:10.1503/jpn.140081

Epstein KA, Kumra S. Executive attention impairment in adolescents with schizophrenia who have used cannabis. Schizophr Res. 2014 Aug;157(1-3):48-54. doi:10.1016/j.schres.2014.04.035

Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, Hart J, Mazzoncini R, Maccabe JH. Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study. Psychiatry Res. 2014 Mar 30;215(3):528-32. doi:10.1016/j.psychres.2013.12.038

Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J Clin Psychiatry. 2014 Apr;75(4):349-56. doi:10.4088/JCP.13m08878

Bernier D, Cookey J., McAllindon D, Bartha R, Hanstock CC, Newman AJ, et al. Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use. BMC Psychiatry. 2013 Oct;13(264):1–13. doi:10.1186/1471-244X-13-264

Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013 Dec;151(1-3):197-202. doi:10.1016/j.schres.2013.10.018

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr Bull. 2013 Mar;39(2):251-4. doi:10.1093/schbul/sbs188

Cunha PJ, Rosa PG, Ayres Ade M, Duran FL, Santos LC, Scazufca M, Menezes PR, dos Santos B, Murray RM, Crippa JA, Busatto GF, Schaufelberger MS. Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res. 2013 Jul;147(2-3):209-15. doi:10.1016/j.schres.2013.04.009

Proal AC, Fleming J, Galvez-Buccollini JA, Delisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res. 2014 Jan;152(1):283-8. doi:10.1016/j.schres.2013.11.014

Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2012 Jun;38(4):873-80. doi:10.1093/schbul/sbq153

Anglin DM, Corcoran CM, Brown AS, Chen H, Lighty Q, Brook JS, Cohen PR. Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophr Res. 2012 May;137(1-3):45-9. doi:10.1016/j.schres.2012.01.019

Galvez-Buccollini JA, Proal AC, Tomaselli V, Trachtenberg M, Coconcea C, Chun J, Delisi LE. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res. 2012 Aug;139(1-3):157–160. doi:10.1016/j.schres.2012.06.007

Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res. 2011 May;128(1-3):66-75. doi:10.1016/j.schres.2011.02.021

Welch KA, McIntosh AM, Job DE, Whalley HC, Moorhead TW, Hall J, et al. The Impact of Substance Use on Brain Structure in People at High Risk of Developing Schizophrenia. Schizophr Bull. 2011 Sep;37(5):1066–1076. doi:10.1093/schbul/sbq013

Welch KA, Stanfield AC, McIntosh AM, Whalley HC, Job DE, Moorhead TW, et al. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry. 2011 Nov;199(5):386-90. doi:10.1192/bjp.bp.110.090175

Compton MT, Broussard B, Ramsay CE, Stewart T. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res. 2011 Mar;126(1-3):71-6. doi:10.1016/j.schres.2010.10.005

Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, Lorell BS, Kane J. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res. 2010 Jul;120(1-3):101-7. doi:10.1016/j.schres.2010.03.037

Teixeira FMC, Costa LO, Monteiro BMM. [Syndrome of hyperemesis secondary to cannabis use: case report]. Braz J Hea Rev. 2021 Fev;4(1):2815-2820. doi:10.34119/bjhrv4n1-226

Silva RCB. Esquizofrenia: uma revisão. Psicol USP. 2006 Nov;17(4):263–285.

Chadwick B, Miller ML, Hurd YL. Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness. Front Psychiatry. 2013 Oct; 14(4):129. doi:10.3389/fpsyt.2013.00129





Original Papers